Table 3.
Baseline Characteristics of the Patients by Treatment Groups in Study 2
| Olanzapine and probiotics plus dietary fibers | Olanzapine alone | ||||
|---|---|---|---|---|---|
| (N = 30) | (N = 28) | ||||
| Mean | SD | Mean | SD | Normal range | |
| Age, y | 24.60 | 8.65 | 24.21 | 4.65 | |
| Duration of illness, mo | 6.57 | 5.59 | 10.82 | 3.55 | |
| Dose of olanzapine, mg | 17.67 | 4.30 | 18.93 | 1.98 | |
| Weight, kg | 52.49 | 8.23 | 55.61 | 7.52 | |
| Body mass index, kg/m2 | 20.04 | 2.84 | 21.12 | 1.56 | 18.50–23.90 kg/m2 |
| Fasting glucose, mmol/L* | 4.33 | 0.50 | 4.40 | 0.36 | 3.90–6.10 mmol/L |
| Fasting insulin, µIU/mL | 9.55 | 8.19 | 7.79 | 1.65 | 6.40–15.00 uIU/mL |
| IRI | 1.83 | 1.59 | 1.53 | 0.35 | <2.67 |
| Triglyceride, mmol/L* | 1.21 | 1.08 | 0.67 | 0.24 | <1.71 mmol/L |
| Total cholesterol, mmol/L | 3.98 | 0.78 | 3.78 | 0.50 | 2.90–5.20 mmol/L |
| HDL-C, mmol/L | 1.30 | 0.27 | 1.22 | 0.15 | >1.04 mmol/L |
| LDL-C, mmol/L | 2.29 | 0.63 | 2.10 | 0.36 | <3.12 mmol/L |
| Total score of PANSS | 88.70 | 19.00 | 80.07 | 7.30 | |
| N | % | N | % | ||
| Female | 23 | 76.7 | 21 | 75.0 | |
| Male | 7 | 23.3 | 7 | 25.0 | |
Med, median; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*p < .05, compared between the two treatment groups.